These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37899130)

  • 1. Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine.
    Faria C; Gava F; Gravelle P; Valero JG; Dobaño-López C; Van Acker N; Quelen C; Jalowicki G; Morin R; Rossi C; Lagarde JM; Fournié JJ; Ysebaert L; Laurent C; Pérez-Galán P; Bezombes C
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target.
    Dobaño-López C; Valero JG; Araujo-Ayala F; Nadeu F; Gava F; Faria C; Norlund M; Morin R; Bernes-Lasserre P; Arenas F; Grau M; López C; López-Oreja I; Serrat N; Martínez-Farran A; Hernández L; Playa-Albinyana H; Giménez R; Beà S; Campo E; Lagarde JM; López-Guillermo A; Magnano L; Colomer D; Bezombes C; Pérez-Galán P
    Blood Cancer J; 2024 May; 14(1):75. PubMed ID: 38697976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses.
    Araujo-Ayala F; Dobaño-López C; Valero JG; Nadeu F; Gava F; Faria C; Norlund M; Morin R; Bernes-Lasserre P; Serrat N; Playa-Albinyana H; Giménez R; Campo E; Lagarde JM; López-Guillermo A; Gine E; Colomer D; Bezombes C; Pérez-Galán P
    Leukemia; 2023 Jun; 37(6):1311-1323. PubMed ID: 37031299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological analysis of immunohistochemical expression of immune checkpoint molecules in follicular lymphoma.
    Yanagida E; Miyoshi H; Takeuchi M; Shimono J; Nakashima K; Yamada K; Kawamoto K; Moritsubo M; Shimasaki Y; Inoue K; Imamoto T; Furuta T; Kohno K; Ohshima K
    Hematol Oncol; 2022 Oct; 40(4):530-540. PubMed ID: 35122292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD1 distribution pattern, regardless of the cell origin, is an independent microenvironmental prognostic factor for progression-free survival in follicular lymphoma.
    Szumera-Ciećkiewicz A; Poleszczuk J; Kuczkiewicz-Siemion O; Paszkiewicz-Kozik E; Rymkiewicz G; Sokół K; Borysiuk A; Kotarska M; Kawecka M; Owczarek D; Pytlak B; Walewski J; Prochorec-Sobieszek M
    Pathol Res Pract; 2020 Oct; 216(10):153096. PubMed ID: 32853965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
    Josefsson SE; Huse K; Kolstad A; Beiske K; Pende D; Steen CB; Inderberg EM; Lingjærde OC; Østenstad B; Smeland EB; Levy R; Irish JM; Myklebust JH
    Clin Cancer Res; 2018 Feb; 24(4):870-881. PubMed ID: 29217528
    [No Abstract]   [Full Text] [Related]  

  • 7. A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment.
    Kastenschmidt JM; Schroers-Martin JG; Sworder BJ; Sureshchandra S; Khodadoust MS; Liu CL; Olsen M; Kurtz DM; Diehn M; Wagar LE; Alizadeh AA
    Cell Stem Cell; 2024 Mar; 31(3):410-420.e4. PubMed ID: 38402619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follicular Lymphoma: The Role of the Tumor Microenvironment in Prognosis.
    Sugimoto T; Watanabe T
    J Clin Exp Hematop; 2016; 56(1):1-19. PubMed ID: 27334853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.
    Myklebust JH; Irish JM; Brody J; Czerwinski DK; Houot R; Kohrt HE; Timmerman J; Said J; Green MR; Delabie J; Kolstad A; Alizadeh AA; Levy R
    Blood; 2013 Feb; 121(8):1367-76. PubMed ID: 23297127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
    Xie M; Huang X; Ye X; Qian W
    Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the multi-omics landscape of follicular lymphoma.
    Xu T; Zheng Z; Zhao W
    Int J Biol Sci; 2023; 19(6):1955-1967. PubMed ID: 37063433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma.
    Voo KS; Foglietta M; Percivalle E; Chu F; Nattamai D; Harline M; Lee ST; Bover L; Lin HY; Baladandayuthapani V; Delgado D; Luong A; Davis RE; Kwak LW; Liu YJ; Neelapu SS
    Int J Cancer; 2014 Dec; 135(12):2834-46. PubMed ID: 24771328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of tissue-infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysis.
    Xie M; Jiang Q; Zhao S; Zhao J; Ye X; Qian W
    Int Immunopharmacol; 2020 Aug; 85():106684. PubMed ID: 32540726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry.
    Liu L; Yu X; Li Z; He X; Zha J; Lin Z; Hong Y; Zheng H; Lai Q; Ding K; Jia X; Fu G; Yu H; Yang H; Li Z; Young KH; Xu B
    J Hematol Oncol; 2022 Aug; 15(1):115. PubMed ID: 35996180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential.
    Watanabe T
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 in T cells from patients with non-Hodgkin lymphoma.
    Huang S; Liang C; Zhao Y; Deng T; Tan J; Lu Y; Liu S; Li Y; Chen S
    Asia Pac J Clin Oncol; 2022 Feb; 18(1):143-149. PubMed ID: 33608984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
    Armand P; Janssens A; Gritti G; Radford J; Timmerman J; Pinto A; Mercadal Vilchez S; Johnson P; Cunningham D; Leonard JP; Rodig SJ; Martín-Regueira P; Sumbul A; Samakoglu S; Tang H; Ansell SM
    Blood; 2021 Feb; 137(5):637-645. PubMed ID: 32870269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm.
    Laurent C; Dietrich S; Tarte K
    Blood; 2024 Mar; 143(12):1080-1090. PubMed ID: 38096368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in Follicular Lymphoma.
    Yang ZZ; Kim HJ; Wu H; Jalali S; Tang X; Krull JE; Ding W; Novak AJ; Ansell SM
    Clin Cancer Res; 2020 Oct; 26(19):5217-5231. PubMed ID: 32631956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass Cytometry Analysis Reveals that Specific Intratumoral CD4
    Yang ZZ; Kim HJ; Villasboas JC; Price-Troska T; Jalali S; Wu H; Luchtel RA; Polley MC; Novak AJ; Ansell SM
    Cell Rep; 2019 Feb; 26(8):2178-2193.e3. PubMed ID: 30784598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.